# Generic Mounjaro, Zepbound May Be Coming, Rivaling Current GLP-1s
Generic versions of Mounjaro and Zepbound could soon enter the market, potentially disrupting the GLP-1 receptor agonist landscape and lowering costs for millions of patients taking these medications for weight loss and diabetes management.
Mounjaro (tirzepatide), manufactured by Eli Lilly, works differently than other GLP-1 drugs. It targets two hormone receptors—GLP-1 and GIP—making it a dual-action medication. Zepbound represents the weight-loss formulation of the same drug. Both medications have dominated recent prescription trends, with demand far outpacing supply at various points since their launches.
Generic competition typically arrives after patent protections expire, driving prices down substantially. For GLP-1 drugs currently on the market, semaglutide (Ozempic, Wegovy) and tirzepatide represent the two most prescribed options. Patients switching from brand-name versions to generics could save hundreds of dollars monthly, depending on insurance coverage and dosage.
The timeline for generic tirzepatide remains unclear, but pharmaceutical companies are likely preparing to file abbreviated new drug applications once patents begin expiring. The original patents on tirzepatide extend several years into the future, though additional patent expirations may occur sooner for specific formulations or delivery mechanisms.
Entry of generics would reshape the competitive landscape. Rival GLP-1 manufacturers, including Novo Nordisk with its semaglutide products, would face pricing pressure. Patients currently on brand-name medications or those unable to access them due to cost would gain more affordable options.
The demand for GLP-1 medications remains high. Obesity affects roughly one-third of American adults, and these